US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Novartis AG

113.08

-1.2100-1.06%

Post-market: 113.090.0100+0.01%18:43 EDT

Volume:1.19M

Turnover:134.83M

Market Cap:223.34B

PE:17.73

High:114.16

Open:114.10

Low:112.70

Close:114.29

Loading ...

Overview Company News Filings

FDA approves Novartis radioligand therapy Pluvicto for earlier use in mCRPC

FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer

Novus Holdings Says TRP Withdraws Approval Of Co's Firm Intention Announcement

Here's Why Novartis (NVS) is a Strong Value Stock

Novartis AG Rises Thursday, Outperforms Market

Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis

Novartis AG Falls Monday, Underperforms Market

Alnylam Gets FDA Nod for Expanded Use of Amvuttra in Cardiomyopathy

Pharma Stock Roundup: PFE's Final Haleon Stake Sale, AZN, SNY M&A Deals

FDA Approves Expanded Use Of Novartis Rare Disease Drug As Only Treatment For Rare Type Of Kidney Disease

Novartis Gets FDA Clearance for First Approved Treatment For Rare Kidney Disease

MT Newswires Live

Novartis gets third FDA approval for oral Fabhalta

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)

Novartis’s treatment of leishmaniasis granted FDA orphan designation

Novartis Reports Updated Positive Data From Phase III SMA Program

Novartis New Data From Single-Dose Gene Therapy Shows Meaningful Efficacy, Safety In Patients With Spinal Muscular Atrophy

Are You Looking for a High-Growth Dividend Stock?

Sector Update: Health Care Stocks Decline Premarket Monday

MT Newswires Live

Market Chatter: Novartis Tracking US Reciprocal Tariff Policy 'Very Carefully'

MT Newswires Live

Novartis Growth Outlook Clouded by Patent Expiries, Pipeline Concerns -- Market Talk

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NVS/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NVS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVS\",,,,,undefined,":{"symbol":"NVS","market":"US","secType":"STK","nameCN":"Novartis AG","latestPrice":113.08,"timestamp":1746475200000,"preClose":114.29,"halted":0,"volume":1190710,"hourTrading":{"tag":"盘后","latestPrice":113.09,"preClose":113.08,"latestTime":"18:43 EDT","volume":14631,"amount":1654475.8371,"timestamp":1746485006663},"delay":0,"floatShares":1805549286,"shares":1975089248,"eps":6.376718,"marketStatus":"Not Yet Opened","change":-1.21,"latestTime":"05-05 16:00:00 EDT","open":114.1,"high":114.16,"low":112.697,"amount":134834816.83426002,"amplitude":0.012801,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":6.376718,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1746518400000},"marketStatusCode":0,"adr":1,"adrRate":1,"exchange":"NYSE","adjPreClose":114.29,"dividendRate":0.034219,"preHourTrading":{"tag":"盘前","latestPrice":114.12,"preClose":114.29,"latestTime":"09:29 EDT","volume":23155,"amount":2653528.8695300003,"timestamp":1746451799097},"postHourTrading":{"tag":"盘后","latestPrice":113.09,"preClose":113.08,"latestTime":"18:43 EDT","volume":14631,"amount":1654475.8371,"timestamp":1746485006663},"volumeRatio":0.508079,"impliedVol":0.2385,"impliedVolPercentile":0.596},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVS\",,,,,undefined,":{"symbol":"NVS","floatShares":1805549286,"roa":"11.42%","roe":"32.89%","lyrEps":5.916419,"volumeRatio":0.508079,"shares":1975089248,"dividePrice":3.86954,"high":114.16,"amplitude":0.012801,"preClose":114.29,"low":112.697,"week52Low":96.062,"pbRate":"5.82","psRate":"4.20","week52High":120.92,"institutionHeld":0.0333,"latestPrice":113.08,"eps":6.376718,"divideRate":0.034219,"volume":1190710,"delay":0,"ttmEps":6.376718,"open":114.1,"prevYearClose":97.31,"prevWeekClose":114.29,"prevMonthClose":113.49,"prevQuarterClose":111.48,"fiveDayClose":112.63,"twentyDayClose":105.85,"sixtyDayClose":106.98},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NVS\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2523683108","title":"FDA approves Novartis radioligand therapy Pluvicto for earlier use in mCRPC","url":"https://stock-news.laohu8.com/highlight/detail?id=2523683108","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523683108?lang=en_us&edition=fundamental","pubTime":"2025-03-29 01:00","pubTimestamp":1743181210,"startTime":"0","endTime":"0","summary":"Novartis (NVS) announced that the Food and Drug Administration approved Pluvicto for patients with prostate-specific membrane antigen-positive meta...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fda-approves-novartis-radioligand-therapy-pluvicto-for-earlier-use-in-mcrpc?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fda-approves-novartis-radioligand-therapy-pluvicto-for-earlier-use-in-mcrpc?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","IE0002141913.USD","BK4578","NVS","BK4007","BK4588","IE00B4R5TH58.HKD","LU0208291251.USD","BK4532","IE0009355771.USD","LU0070302665.USD","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","LU0211331839.USD","LU0320765489.SGD","IE00BJJMRZ35.SGD"],"gpt_icon":0},{"id":"2523856256","title":"FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2523856256","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523856256?lang=en_us&edition=fundamental","pubTime":"2025-03-29 00:52","pubTimestamp":1743180720,"startTime":"0","endTime":"0","summary":"New indication approximately triples eligible patient population, allowing Pluvicto to be used after one androgen receptor pathway inhibitor  and now before chemotherapy. Pluvicto significantly reduced risk of progression or death by 59% and more than doubled median radiographic progression-free survival  vs. change in ARPI in Phase III PSMAfore trial*. Approximately half of patients do not live long enough to receive a second treatment for mCRPC, highlighting need for earlier use of effective therapies with demonstrated tolerability1. Multiple RLT manufacturing facilities in US fully meet supply needs for expanded indication, with industry-leading infrastructure to accelerate delivery of RLTs to patients. Basel, March 28, 2025 – Novartis announced today that the US Food and Drug Administration  approved Pluvicto  for patients with prostate-specific membrane antigen -positive metastatic castration-resistant prostate cancer  who have been treated with an androgen receptor pathway inhibi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-approves-novartis-radioligand-therapy-165200923.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4097","LU0211331839.USD","LU0208291251.USD","IE0002141913.USD","IE00B2B36J28.USD","BK4578","LU0070302665.USD","IE0009355771.USD","IE00BFTCPJ56.SGD","OS","NVS","LU0320765489.SGD","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","BK4007","BK4532","BK4588","IE00BJJMRZ35.SGD","BK4585"],"gpt_icon":0},{"id":"2523500843","title":"Novus Holdings Says TRP Withdraws Approval Of Co's Firm Intention Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=2523500843","media":"T-Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523500843?lang=en_us&edition=fundamental","pubTime":"2025-03-28 23:17","pubTimestamp":1743175046,"startTime":"0","endTime":"0","summary":"Novus Holdings Ltd :Novus Holdings Ltd - Trp Withdraws Approval Of Novus' Firm Intention Announcement.Novus Holdings Ltd - To Appeal Trp Ruling On Urgent Basis.Novus Holdings Ltd - Trp Directs Novus To Publish Revised Firm Intention Announcement Within 20 Days.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.trkd.thomsonreuters.com","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0211331839.USD","IE00B2B36J28.USD","BK4007","LU0070302665.USD","NVS","BK4578","IE0002141913.USD","IE00BJJMRZ35.SGD","BK4532","LU0320765489.SGD","IE00BFTCPJ56.SGD","LU0208291251.USD","IE00BJT1NW94.SGD","BK4588","IE0009355771.USD","IE00B4R5TH58.HKD","BK4585"],"gpt_icon":0},{"id":"2522850130","title":"Here's Why Novartis (NVS) is a Strong Value Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2522850130","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522850130?lang=en_us&edition=fundamental","pubTime":"2025-03-28 21:40","pubTimestamp":1743169212,"startTime":"0","endTime":"0","summary":"For new and old investors, taking full advantage of the stock market and investing with confidence are common goals.While you may have an investing style you rely on, finding great stocks is made easier with the Zacks Style Scores. These are complementary indicators that rate stocks based on value, growth, and/or momentum characteristics.Why Investors Should Pay Attention to This Value Stock. Finding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, and Price/Cash Flow to highlight the most attractive and discounted stocks.NVS is a Zacks Rank #3  stock, with a Value Style Score of B and VGM Score of B. Shares are currently trading at a forward P/E of 13.2X for the current fiscal year compared to the Large Cap Pharmaceuticals industry's P/E of 14.1X. Additionally, NVS has a PEG Ratio of 1.8 and a Price/Cash Flow ratio of","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/heres-why-novartis-nvs-strong-134012219.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BK4585","IE00B4R5TH58.HKD","IE0002141913.USD","IE00BJJMRZ35.SGD","LU0208291251.USD","IE00BFTCPJ56.SGD","LU0320765489.SGD","IE0009355771.USD","LU0070302665.USD","IE00BJT1NW94.SGD","BK4578","LU0211331839.USD","IE00B2B36J28.USD","NVS","BK4532","BK4588"],"gpt_icon":0},{"id":"2522582985","title":"Novartis AG Rises Thursday, Outperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2522582985","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522582985?lang=en_us&edition=fundamental","pubTime":"2025-03-28 01:15","pubTimestamp":1743095700,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of Novartis AG  rose 1.0% to CHF98.29 Thursday on what proved to be an overall unfavorable trading session for the stock market, with the Swiss SMI Index  falling 0.7% to 12,867.23.The stock's rise snapped a four-day losing streak.Novartis AG closed CHF4.43 below its 52-week high of CHF102.72, which the company reached on September 2, 2024.Trading volume was 3,115,213, compared to the 50-day average trading volume of 4,119,935.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AG","NVS"],"gpt_icon":0},{"id":"2522062797","title":"Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2522062797","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522062797?lang=en_us&edition=fundamental","pubTime":"2025-03-25 14:15","pubTimestamp":1742883300,"startTime":"0","endTime":"0","summary":"Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta in people with relapsing multiple sclerosis. Long-term disability and safety data from ALITHIOS open-label extension study on continuous treatment with Kesimpta vs. later switch from teriflunomide in relapsing multiple sclerosis  patients to be presented. Additional presentations highlight the Novartis neuroscience pipeline, including remibrutinib for RMS and iptacopan for generalized myasthenia gravis. Basel, March 25, 2025 – Novartis will present data from studies across its neuroscience portfolio, including seven-year disability outcomes and safety data from the ALITHIOS open-label extension trial of Kesimpta  in people with relapsing multiple sclerosis , at the American Academy of Neurology  2025 Annual Meeting inSan Diego from April 5-9,2025. Additional data on Kesimpta and pipeline assets including remibrutinib and iptacopan will also be highlighted.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/novartis-present-data-aan-including-061500982.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0211331839.USD","LU0320765489.SGD","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","PT","LU0070302665.USD","NVS","LU0208291251.USD","IE0002141913.USD","AAN","BK4578","BK4588","BK4007","BK4532","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","BK4585","IE0009355771.USD","BK4178","BK4166","IE00BJT1NW94.SGD"],"gpt_icon":0},{"id":"2522708395","title":"Novartis AG Falls Monday, Underperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2522708395","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522708395?lang=en_us&edition=fundamental","pubTime":"2025-03-25 01:15","pubTimestamp":1742836500,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of Novartis AG  dropped 0.7% to CHF98.57 Monday on what proved to be an overall unfavorable trading session for the stock market, with the Swiss SMI Index  falling 0.6% to 13,000.24.This was the stock's second consecutive day of losses.Novartis AG closed CHF4.15 below its 52-week high of CHF102.72, which the company achieved on September 2, 2024.Trading volume was 3,272,988, compared to the 50-day average trading volume of 4,072,328.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AG","NVS"],"gpt_icon":0},{"id":"2521584612","title":"Alnylam Gets FDA Nod for Expanded Use of Amvuttra in Cardiomyopathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2521584612","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521584612?lang=en_us&edition=fundamental","pubTime":"2025-03-22 00:46","pubTimestamp":1742575560,"startTime":"0","endTime":"0","summary":"ALNY’s Amvuttra, an RNAi therapeutic, was previously approved in the United States for treating adult patients with polyneuropathy associated with transthyretin-mediated amyloidosis . It is also marketed in the EU for treating hATTR-PN in adult patients with stage 1 or stage 2 polyneuropathy.The FDA’s latest nod makes Amvuttra the first and only therapeutic approved in the United Statesfor both ATTR-CM and hATTR-PN in adults, marking a significant milestone achievement. ATTR-CM is a severe, rapidly progressing, and life-threatening disease affecting an estimated 150,000 people in the United States and over 300,000 globally. Despite its impact, most cases go undiagnosed and untreated, while many patients receiving standard therapies continue to experience disease progression.The approval of Amvuttra’s supplemental new drug application  for the ATTR-CM indication is based on positiveresults from Alnylam’s pivotal phase III HELIOS-B study of the drug, which met all primary and secondary e","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alnylam-gets-fda-nod-expanded-164600244.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","BK4139","LU0234570918.USD","LU1066051498.USD","ALNY","LU2089984988.USD","IE00BFTCPJ56.SGD","IE0009355771.USD","BK4532","LU1839511570.USD","LU2087621335.USD","LU0058720904.USD","IE00B19Z3B42.SGD","LU0070302665.USD","IE0002270589.USD","BK4548","LU1571399168.USD","LU1066053197.SGD","IE0002141913.USD","NVS","LU0211331839.USD","IE00B19Z3581.USD","BK4550","BK4583","IE00BKVL7J92.USD","LU0208291251.USD","LU0109394709.USD","IE00B4R5TH58.HKD","BK4007","LU0889565916.HKD","LU1585245621.USD","BK4578","IE00B2B36J28.USD","LU1430594728.SGD","IE00B7SZLL34.SGD","LU0289739699.SGD","IE00BZ1G4Q59.USD","IE00BSNM7G36.USD","BK4566","IE00B3T34201.USD","LU0320765489.SGD","DVAX","BK4585","GILD","LU0320765992.SGD","BK4588","BK4568","LU2468319806.SGD"],"gpt_icon":0},{"id":"2521498258","title":"Pharma Stock Roundup: PFE's Final Haleon Stake Sale, AZN, SNY M&A Deals","url":"https://stock-news.laohu8.com/highlight/detail?id=2521498258","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521498258?lang=en_us&edition=fundamental","pubTime":"2025-03-22 00:26","pubTimestamp":1742574360,"startTime":"0","endTime":"0","summary":"This week, the FDA approved J&J’s JNJ Tremfya for its second inflammatory bowel disease  condition, Crohn’s disease , and Novartis’ NVS Fabhalta for its third indication, C3 glomerulopathy . Pfizer PFE sold its remaining 7.3% stake in Haleon, thus fully exiting the consumer health company. Sanofi SNY and AstraZeneca AZN announced small acquisition deals.Here's a recap of the week’s most important stories.Haleon was a consumer health joint venture jointly created by Pfizer and GSK in 2019. GSK owned a controlling stake of 68% in the Consumer Healthcare JV . GSK/Pfizer divested the CHC JV to form Haleon in July 2022. GSK, which initially owned a nearly 13% stake in Haleon, sold its entire stake in May 2024. Pfizer originally held a 32% stake in Haleon, which it had started gradually reducing since 2022.FDA Approves NVS’ Fabhalta for Rare Kidney Disease","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pharma-stock-roundup-pfes-final-162600943.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BFTCPJ56.SGD","LU2236285917.USD","SG9999003800.SGD","LU2505996509.AUD","LU1585245621.USD","BK4592","LU0320765646.SGD","LU1829250122.USD","LU0225771236.USD","LU1066051498.USD","LU1221951046.USD","BK4581","LU1267930813.SGD","BK4183","LU0058720904.USD","LU2129689514.USD","LU1221951129.SGD","SNY","NVS","LU0225284248.USD","LU1778281490.HKD","LU2430703178.SGD","LU1280957306.USD","LU1057294990.SGD","PFE","LU0234570918.USD","IE00B19Z3B42.SGD","SG9999011175.SGD","LU2430703095.HKD","LU2592432038.USD","IE00BJJMRZ35.SGD","JNJ","LU2462157665.USD","LU0985481810.HKD","LU0098860793.USD","BK4550","LU0109394709.USD","LU1674673691.USD","LU1506573853.SGD","SG9999002232.USD","BK4532","LU2129689605.HKD","SG9999002224.SGD","LU0795875169.SGD","LU0889566641.SGD","LU1732800096.USD","BK4007","HLN","IE00BLSP4239.USD","AZN"],"gpt_icon":1},{"id":"2521317582","title":"FDA Approves Expanded Use Of Novartis Rare Disease Drug As Only Treatment For Rare Type Of Kidney Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2521317582","media":"Benzinga","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521317582?lang=en_us&edition=fundamental","pubTime":"2025-03-21 23:36","pubTimestamp":1742571368,"startTime":"0","endTime":"0","summary":"On Thursday, the U.S. Food and Drug Administration  approved Novartis AG’s  oral Fabhalta for adults with C3 glomerulopathy  to reduce proteinuria , making it the first and only treatment approved for this condition.C3G isa rare kidney disease characterized by damage to the glomeruli  due to dysregulation of the complement system, specifically the alternative pathway, leading to C3 protein accumulation.Also Read: Novartis New Data From Single-Dose Gene Therapy Shows Meaningful Efficacy, Safety In Patients With Spinal Muscular Atrophy. The pivotal Phase 3 APPEAR-C3G study evaluated the efficacy and safety of twice-daily oral Fabhalta in adult patients with C3G.Treatment with Fabhalta resulted in a clinically meaningful reduction in proteinuria, which was seen as early as 14 days and sustained at 12 months.Last month, Fabhalta received a positive CHMP Opinion in C3G by the European Medicines Agency . Regulatory reviews for this indication are ongoing inChinaand Japan.This is the third US","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-approves-expanded-novartis-rare-153608883.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"FDA Approves Expanded Use Of Novartis Rare Disease Drug As Only Treatment For Rare Type Of Kidney Disease","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BFTCPJ56.SGD","BK4588","IE00B4R5TH58.HKD","LU0070302665.USD","BK4585","LU0320765489.SGD","BK4532","IE00BJT1NW94.SGD","LU0211331839.USD","IE0009355771.USD","LU0208291251.USD","IE00BJJMRZ35.SGD","BK4578","IE0002141913.USD","NVS","IE00B2B36J28.USD","BK4007"],"gpt_icon":0},{"id":"2521474597","title":"Novartis Gets FDA Clearance for First Approved Treatment For Rare Kidney Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2521474597","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521474597?lang=en_us&edition=fundamental","pubTime":"2025-03-21 17:07","pubTimestamp":1742548037,"startTime":"0","endTime":"0","summary":"Novartis  said Thursday the US Food and Drug Administration has approved Fabhalta to treat adults with C3 glomerulopathy, the first therapy cleared for the condition.The oral drug is designed to reduce protein in urine and targets a part of the immune system thought to drive the disease, the company said.Data from a phase 3 trial showed a sustained drop in protein levels over one year, with no unexpected safety issues reported.C3G is an uncommon kidney disorder usually diagnosed in young adults and often ends in kidney failure within a decade, according to Novartis.The company said the treatment is also being reviewed in other regions, including Europe, China, and Japan.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE0009355771.USD","IE00BJT1NW94.SGD","LU0208291251.USD","BK4585","LU0070302665.USD","IE0002141913.USD","NVS","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","LU0211331839.USD","LU0320765489.SGD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","BK4007","BK4578","BK4588","BK4532"],"gpt_icon":0},{"id":"2521141426","title":"Novartis gets third FDA approval for oral Fabhalta","url":"https://stock-news.laohu8.com/highlight/detail?id=2521141426","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521141426?lang=en_us&edition=fundamental","pubTime":"2025-03-21 08:45","pubTimestamp":1742517910,"startTime":"0","endTime":"0","summary":"The company states: “Novartis (NVS) announced that oral Fabhalta, iptacopan, has received U.S. Food and Drug Administration approval for the treatm...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novartis-gets-third-fda-approval-for-oral-fabhalta?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novartis-gets-third-fda-approval-for-oral-fabhalta?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","IE00BFTCPJ56.SGD","LU0320765489.SGD","IE00BJJMRZ35.SGD","IE0009355771.USD","IE00B2B36J28.USD","BK4532","NVS","LU0211331839.USD","BK4007","IE00BJT1NW94.SGD","IE0002141913.USD","IE00B4R5TH58.HKD","BK4578","LU0208291251.USD","LU0070302665.USD","BK4588"],"gpt_icon":0},{"id":"2521741570","title":"Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)","url":"https://stock-news.laohu8.com/highlight/detail?id=2521741570","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521741570?lang=en_us&edition=fundamental","pubTime":"2025-03-21 07:37","pubTimestamp":1742513820,"startTime":"0","endTime":"0","summary":"Phase III study showed sustained proteinuria reduction at one year with favorable safety1. C3G is an ultra-rare kidney disease typically diagnosed in young adults and often progresses to kidney failure2-4. Novartis continues to advance multiple kidney disease treatments with high unmet need, compounding capabilities and strengthening unique leadership presence. EAST HANOVER, N.J., March 20, 2025 /PRNewswire/ -- Novartis today announced that oral Fabhalta  has received U.S. Food and Drug Administration  approval for the treatment ofadults with C3 glomerulopathy , to reduce proteinuria, making it the first and only treatment approved for this condition1-4.Fabhalta is the only oral inhibitor of the alternative complement pathway to selectively target what is thought to be the underlying cause of the disease1-3. Before the approval of Fabhalta, patients had to rely on supportive care, broad immunosuppression, and symptom management5-6.Data supporting approval The pivotal Phase III APPEAR-C","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/novartis-receives-third-fda-approval-233700715.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/novartis-receives-third-fda-approval-233700715.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0208291251.USD","LU0320765489.SGD","BK4007","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","IE0009355771.USD","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","BK4585","IE00B4R5TH58.HKD","LU0211331839.USD","BK4532","BK4588","LU0070302665.USD","NVS","BK4578","IE0002141913.USD"],"gpt_icon":0},{"id":"2521418159","title":"Novartis’s treatment of leishmaniasis granted FDA orphan designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2521418159","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521418159?lang=en_us&edition=fundamental","pubTime":"2025-03-21 06:25","pubTimestamp":1742509535,"startTime":"0","endTime":"0","summary":"Novartis’s (NVS) parasite-selective proteasome inhibitor with potent activity against kinetoplastid parasites was granted FDA orphan designation fo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novartiss-treatment-of-leishmaniasis-granted-fda-orphan-designation?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novartiss-treatment-of-leishmaniasis-granted-fda-orphan-designation?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0211331839.USD","IE0009355771.USD","BK4532","LU0320765489.SGD","IE00BJT1NW94.SGD","BK4007","LU0208291251.USD","BK4578","IE0002141913.USD","NVS","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","BK4585","LU0070302665.USD","IE00B2B36J28.USD","BK4588","IE00B4R5TH58.HKD"],"gpt_icon":0},{"id":"2520468110","title":"Novartis Reports Updated Positive Data From Phase III SMA Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2520468110","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520468110?lang=en_us&edition=fundamental","pubTime":"2025-03-20 21:34","pubTimestamp":1742477640,"startTime":"0","endTime":"0","summary":"NovartisNVS reported promising new safety and efficacy results from its phase III studies of investigational intrathecal onasemnogene abeparvovec  in a broad group of patients aged 2 to under 18 years with spinal muscular atrophy . OAV101 IT is an investigational, one-time gene therapy for patients with SMA.Additionally, in the phase IIIb STRENGTH study, treatment with OAV101 IT demonstrated stabilization of motor function over 52 weeks of follow-up in patients who had previously discontinued treatment with Spinraza  or Roche’s RHHBY Evrysdi .SMA, a rare, genetic neuromuscular disease caused by a lack of a functional SMN1 gene, results in the irreversible loss of motor neurons, affecting muscle functions, including breathing, swallowing and basic movement.Year to date, shares of Novartis have gained 14.6% compared with the industry’s 7.2% growth.Novartis presented these data at a recent medical conference held in Dallas, Texas. Per NVS, OAV101 IT is the first investigational gene repla","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/novartis-reports-updated-positive-data-133400414.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B4R5TH58.HKD","BK4139","IE00BKVL7J92.USD","LU1066053197.SGD","IE0002141913.USD","III","LU1066051498.USD","BK4568","BK4134","BK4566","IE00B3T34201.USD","RHHBY","IE00BSNM7G36.USD","LU0208291251.USD","LU0109394709.USD","LU2089984988.USD","IE00BZ1G4Q59.USD","03165","NVS","BK4583","IE00BFTCPJ56.SGD","LU1839511570.USD","IE0002270589.USD","BK4532","IE0009355771.USD","BK4007","BK4578","IE00BJT1NW94.SGD","IE00B19Z3B42.SGD","LU0320765489.SGD","LU1430594728.SGD","BK4588","IE00B7SZLL34.SGD","GILD","BK4585","LU0234570918.USD","LU0889565916.HKD","LU2468319806.SGD","LU0211331839.USD","LU1571399168.USD","LU2087621335.USD","LU0058720904.USD","IE00BJJMRZ35.SGD","LU0289739699.SGD","LU0070302665.USD","LU0320765992.SGD","LU1585245621.USD","BK4550","IE00B19Z3581.USD","DVAX"],"gpt_icon":0},{"id":"2520168133","title":"Novartis New Data From Single-Dose Gene Therapy Shows Meaningful Efficacy, Safety In Patients With Spinal Muscular Atrophy","url":"https://stock-news.laohu8.com/highlight/detail?id=2520168133","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520168133?lang=en_us&edition=fundamental","pubTime":"2025-03-20 01:09","pubTimestamp":1742404163,"startTime":"0","endTime":"0","summary":"On Wednesday, Novartis AG  announced safety and efficacy results from the Phase 3 program for investigational intrathecal onasemnogene abeparvovec  in a broad population of patients aged two to <18 years with spinal muscular atrophy .In the Phase 3 STEER study, treatment with OAV101 IT led to a statistically significant 2.39-point improvement on the Hammersmith Functional Motor Scale Expanded , an assessment of motor ability and disease progression, vs. 0.51 points in the sham control arm.Also Read: Novartis To Beef Up Heart Disease Offering With $3 Billion Blackstone-Backed Anthos Therapeutics Deal. Novartis released topline data from the Phase 3 STEER study in December 2024.The results add to the growing body of evidence within the OAV101 IT development program, which has evaluated a broad population of over 170 patients with SMA, spanning a total of over 6.4 years across the STEER, STRENGTH, and Phase 1/2 STRONG studies.In the registrational STEER study, efficacy and safety were stu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/novartis-data-single-dose-gene-170923739.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B4R5TH58.HKD","BK4139","IE0002141913.USD","IE00B19Z9P08.USD","IE00B2B36J28.USD","IE00B894F039.SGD","LU0208291251.USD","LU0109394709.USD","NVS","IE00BFTCPJ56.SGD","BK4532","IE00BJT1NW94.SGD","IE0009355771.USD","BK4533","BK4578","BK4007","LU0320765489.SGD","BK4588","BK4585","IE00B19Z9Z06.USD","LU0234570918.USD","LU0889565916.HKD","LU0211331839.USD","BIIB","IE00BJJMRZ35.SGD","LU0070302665.USD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2520205570","title":"Are You Looking for a High-Growth Dividend Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2520205570","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520205570?lang=en_us&edition=fundamental","pubTime":"2025-03-17 23:45","pubTimestamp":1742226311,"startTime":"0","endTime":"0","summary":"Getting big returns from financial portfolios, whether through stocks, bonds, ETFs, other securities, or a combination of all, is an investor's dream. But for income investors, generating consistent cash flow from each of your liquid investments is your primary focus.While cash flow can come from bond interest or interest from other types of investments, income investors hone in on dividends. A dividend is the distribution of a company's earnings paid out to shareholders; it's often viewed by its dividend yield, a metric that measures a dividend as a percent of the current stock price. Many academic studies show that dividends make up large portions of long-term returns, and in many cases, dividend contributions surpass one-third of total returns.Based in Basel, Novartis  is in the Medical sector, and so far this year, shares have seen a price change of 12.07%. The drugmaker is paying out a dividend of $2.52 per share at the moment, with a dividend yield of 2.31% compared to the Large ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/looking-high-growth-dividend-stock-154511587.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE0002141913.USD","IE00BFTCPJ56.SGD","IE0009355771.USD","BK4588","BK4532","BK4578","IE00B2B36J28.USD","LU0211331839.USD","NVS","BK4007","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","LU0070302665.USD","LU0208291251.USD","LU0320765489.SGD","BK4585","IE00B4R5TH58.HKD"],"gpt_icon":0},{"id":"2520529493","title":"Sector Update: Health Care Stocks Decline Premarket Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=2520529493","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520529493?lang=en_us&edition=fundamental","pubTime":"2025-03-17 21:12","pubTimestamp":1742217155,"startTime":"0","endTime":"0","summary":"Health care stocks declined premarket Monday with the Health Care Select Sector SPDR Fund  0.3% lower and the iShares Biotechnology ETF  down 0.9% recently.Avidity Biosciences Inc  shares advanced by over 3% after the company said topline data from the phase 1/2 EXPLORE44 trial of del-zota to treat Duchenne muscular dystrophy showed \"consistent, statistically significant improvements in dystrophin, exon skipping and creatine kinase.\"Dyne Therapeutics  shares were up over 4% after the company said long-term clinical data from an ongoing phase 1/2 clinical trial of its investigational drug DYNE-251 is showing a \"clinically meaningful and sustained functional improvement\" in patients with Duchenne muscular dystrophy.Novartis  is tracking the Trump administration's proposed reciprocal tariff policy \"very carefully\" and will respond accordingly once the policy is implemented next month, Reuters reported, citing Novartis Chief Executive Vas Narasimhan. Novartis shares were over 1% higher pre","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BFTCPJ56.SGD","IBB","IE00BJJMRZ35.SGD","LU0208291251.USD","BK4585","BK4139","DYN","BK4578","BK4007","IE0002141913.USD","NVS","BK4581","XLV","IE0009355771.USD","BK4505","BK4532","IE00B2B36J28.USD","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","RNA","LU0211331839.USD","LU0070302665.USD","LU0320765489.SGD","BK4588"],"gpt_icon":0},{"id":"2520514404","title":"Market Chatter: Novartis Tracking US Reciprocal Tariff Policy 'Very Carefully'","url":"https://stock-news.laohu8.com/highlight/detail?id=2520514404","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520514404?lang=en_us&edition=fundamental","pubTime":"2025-03-17 17:46","pubTimestamp":1742204792,"startTime":"0","endTime":"0","summary":"Novartis  is tracking the Trump administration's proposed reciprocal tariff policy \"very carefully\" and will respond accordingly once the policy is implemented next month, Reuters reported Monday, citing Novartis Chief Executive Vas Narasimhan.\"The real key is to see what are the policies that are actually implemented versus what's being said in the rhetoric,\" Narasimhan reportedly said. \"And then we're just going to have to respond appropriately.\"The Swiss pharmaceutical giant didn't immediately respond to MT Newswires' request for comment.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","LU0211331839.USD","IE0009355771.USD","BK4532","BK4585","IE0002141913.USD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","LU0070302665.USD","BK4578","IE00BJJMRZ35.SGD","LU0320765489.SGD","BK4007","LU0208291251.USD","NVS","BK4588"],"gpt_icon":0},{"id":"2520989175","title":"Novartis Growth Outlook Clouded by Patent Expiries, Pipeline Concerns -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2520989175","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520989175?lang=en_us&edition=fundamental","pubTime":"2025-03-17 15:34","pubTimestamp":1742196840,"startTime":"0","endTime":"0","summary":"0734 GMT - Novartis's 2025 guidance signals a slowdown in the growth outlook as patent expiries begin and pipeline catalysts are lacking, Berenberg analyst Kerry Holford says in a note. \"In our view, Novartis is fully valued, pricing in a positive pipeline regeneration gap, which we struggle to support given its poor historical returns on R&D investment,\" she says. The Swiss pharma company will release a late-stage trial of its treatment for Sjogren's syndrome in the second half of the year, Holford says. However, more significant results are expected next year, such as the late-stage trial of cardiovascular disease prevention pelacarsen and thrombosis treatment abelacimab, the analyst says. ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0208291251.USD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","LU0070302665.USD","IE0002141913.USD","IE00B4R5TH58.HKD","BK4532","LU0211331839.USD","BK4578","BK4585","BK4007","LU0320765489.SGD","IE00BFTCPJ56.SGD","NVS","BK4588","IE00BJJMRZ35.SGD","IE0009355771.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":5,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-04-29","symbol":"NVS","fiscalQuarterEnding":"2025/03","expectedEps":2.12,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1745899200000,"reportTimeType":"pre","actualEps":2.28},{"date":"2025-03-12","symbol":"NVS","amount":3.86954,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-12","defaultRemindTime":1741786200000,"name":"诺华","lastCurrency":null,"lastExecuteDate":null,"recordDate":null,"payableDate":"2025-03-12","currency":"USD","dateTimestamp":1741752000000,"payDate":null},{"market":"US","date":"2025-01-31","symbol":"NVS","fiscalQuarterEnding":"2024/12","expectedEps":1.81,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1738299600000,"reportTimeType":"pre","actualEps":1.98},{"market":"US","date":"2024-10-29","symbol":"NVS","fiscalQuarterEnding":"2024/09","expectedEps":1.94,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1730174400000,"reportTimeType":"pre","actualEps":2.06},{"market":"US","date":"2024-07-18","symbol":"NVS","fiscalQuarterEnding":"2024/06","expectedEps":1.87,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1721275200000,"reportTimeType":"pre","actualEps":1.97}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVS\",market:\"US\",,,undefined,":[{"executeDate":"2016-02-24","recordDate":"2016-02-26","paymentDate":"2016-04-15","value":2.302755,"currency":"USD"},{"executeDate":"2019-03-04","recordDate":"2019-03-05","paymentDate":"2019-03-13","value":1.861996,"currency":"USD"},{"executeDate":"2020-03-03","recordDate":"2020-03-04","paymentDate":"2020-03-12","value":1.9776197,"currency":"USD"},{"executeDate":"2021-03-04","recordDate":"2021-03-05","paymentDate":"2021-03-15","value":2.1959459,"currency":"USD"},{"executeDate":"2022-03-08","recordDate":"2022-03-09","paymentDate":"2022-03-17","value":3.3574492,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NVS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.1,"hold":0.6,"sell":0.3,"strongSell":0,"meanLabel":"HOLD","meanPercent":0.6,"analysts":10,"updateTime":1744344000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NVS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NVS","date":"2025-05-02","current":17.243172,"percent":0.441558,"low":7.087581,"twenty":9.17305,"median":18.728326,"eighty":26.564795,"high":33.848621,"avg":18.947103,"sd":7.684795,"marketCap":221729945789.59},"quantilePoints":[{"date":"2020-05-08","current":16.06719,"twenty":15.022068,"median":17.611494,"eighty":28.067058,"marketCap":195087824511.38},{"date":"2020-05-15","current":15.133928,"twenty":15.029105,"median":17.577522,"eighty":28.059696,"marketCap":183756150779.48},{"date":"2020-05-22","current":15.343364,"twenty":15.030337,"median":17.539345,"eighty":28.029058,"marketCap":186299125645.41},{"date":"2020-05-29","current":15.670723,"twenty":15.048567,"median":17.506592,"eighty":28.022419,"marketCap":190273917101.96},{"date":"2020-06-05","current":15.653235,"twenty":15.05741,"median":17.491087,"eighty":28.017268,"marketCap":190061581744.23},{"date":"2020-06-12","current":15.30119,"twenty":15.060887,"median":17.476205,"eighty":27.997804,"marketCap":185787049141.61},{"date":"2020-06-19","current":16.556853,"twenty":15.077447,"median":17.466898,"eighty":27.987006,"marketCap":201033316893.8},{"date":"2020-06-26","current":15.916169,"twenty":15.084669,"median":17.460565,"eighty":27.982482,"marketCap":193254122511.55},{"date":"2020-07-02","current":15.939875,"twenty":15.096906,"median":17.438742,"eighty":27.965467,"marketCap":193541959173.38},{"date":"2020-07-10","current":15.827476,"twenty":15.105726,"median":17.415673,"eighty":27.932834,"marketCap":192177214934.9},{"date":"2020-07-17","current":15.909995,"twenty":15.108152,"median":17.408633,"eighty":27.905383,"marketCap":193179148808.17},{"date":"2020-07-24","current":25.866578,"twenty":15.110436,"median":17.413902,"eighty":27.890944,"marketCap":186498028239.8},{"date":"2020-07-31","current":25.307939,"twenty":15.11173,"median":17.428065,"eighty":27.882963,"marketCap":182470241873.48},{"date":"2020-08-07","current":25.275976,"twenty":15.12518,"median":17.460369,"eighty":27.855072,"marketCap":182239790737.98},{"date":"2020-08-14","current":25.963677,"twenty":15.136152,"median":17.46483,"eighty":27.822479,"marketCap":187198114700.06},{"date":"2020-08-21","current":26.31296,"twenty":15.145226,"median":17.469399,"eighty":27.751331,"marketCap":189716446657.38},{"date":"2020-08-28","current":26.432206,"twenty":15.157076,"median":17.490797,"eighty":27.687759,"marketCap":190576209962.38},{"date":"2020-09-04","current":26.289955,"twenty":15.163392,"median":17.505765,"eighty":27.512066,"marketCap":189550574045.52},{"date":"2020-09-11","current":27.499584,"twenty":15.165426,"median":17.535576,"eighty":27.461844,"marketCap":198272000195.83},{"date":"2020-09-18","current":27.874868,"twenty":15.167813,"median":17.566173,"eighty":27.688711,"marketCap":200977799366.41},{"date":"2020-09-25","current":26.408027,"twenty":15.174934,"median":17.592165,"eighty":27.663643,"marketCap":190401873862.84},{"date":"2020-10-02","current":26.708229,"twenty":15.183274,"median":17.637235,"eighty":27.633307,"marketCap":192566335706.05},{"date":"2020-10-09","current":27.059181,"twenty":15.18461,"median":17.670441,"eighty":27.56422,"marketCap":195096692723.52},{"date":"2020-10-16","current":26.362521,"twenty":15.18744,"median":17.737178,"eighty":27.461844,"marketCap":190073773914.09},{"date":"2020-10-23","current":25.797382,"twenty":15.190989,"median":17.775785,"eighty":27.402807,"marketCap":185999119226.86},{"date":"2020-10-30","current":24.988388,"twenty":15.193883,"median":17.792728,"eighty":27.388696,"marketCap":177492523698.86},{"date":"2020-11-06","current":27.216027,"twenty":15.199589,"median":17.829937,"eighty":27.357723,"marketCap":193315439822.18},{"date":"2020-11-13","current":27.485895,"twenty":15.20954,"median":17.865475,"eighty":27.402807,"marketCap":195232311745.39},{"date":"2020-11-20","current":27.977491,"twenty":15.21419,"median":17.948734,"eighty":27.570986,"marketCap":198724117569.53},{"date":"2020-11-27","current":28.696184,"twenty":15.217792,"median":17.957315,"eighty":27.667977,"marketCap":203828990967.78},{"date":"2020-12-04","current":29.177337,"twenty":15.226366,"median":17.977434,"eighty":27.722608,"marketCap":207246629519.95},{"date":"2020-12-11","current":29.329405,"twenty":15.231613,"median":17.986357,"eighty":27.833026,"marketCap":208326758462.39},{"date":"2020-12-18","current":29.122537,"twenty":15.23366,"median":17.997105,"eighty":27.894825,"marketCap":206857381598.42},{"date":"2020-12-24","current":28.223441,"twenty":15.238838,"median":18.012439,"eighty":27.939463,"marketCap":200471097283.05},{"date":"2020-12-31","current":30.275456,"twenty":15.242355,"median":18.038048,"eighty":27.982482,"marketCap":215046563030.23},{"date":"2021-01-08","current":30.050051,"twenty":15.243996,"median":18.077533,"eighty":28.022419,"marketCap":213445512050.29},{"date":"2021-01-15","current":30.69708,"twenty":15.252301,"median":18.087632,"eighty":28.087076,"marketCap":218041359312.66},{"date":"2021-01-22","current":31.075017,"twenty":15.257047,"median":18.107937,"eighty":28.154132,"marketCap":220725844580.34},{"date":"2021-01-29","current":25.302982,"twenty":15.267282,"median":18.143206,"eighty":28.154132,"marketCap":204245667129.31},{"date":"2021-02-05","current":25.307678,"twenty":15.27441,"median":18.16572,"eighty":28.138918,"marketCap":204283575482.98},{"date":"2021-02-12","current":25.723524,"twenty":15.27628,"median":18.200034,"eighty":28.125839,"marketCap":207640289409.26},{"date":"2021-02-19","current":24.769133,"twenty":15.278711,"median":18.210204,"eighty":28.104835,"marketCap":199936445479.85},{"date":"2021-02-26","current":24.064713,"twenty":15.284399,"median":18.226261,"eighty":28.073741,"marketCap":194250364295.15},{"date":"2021-03-05","current":23.084461,"twenty":15.288901,"median":18.233974,"eighty":28.064113,"marketCap":186337768880.54},{"date":"2021-03-12","current":23.435071,"twenty":15.291775,"median":18.240532,"eighty":28.047441,"marketCap":189167893568.67},{"date":"2021-03-19","current":24.013766,"twenty":15.297229,"median":18.250058,"eighty":28.025738,"marketCap":193839113911.88},{"date":"2021-03-26","current":24.361283,"twenty":15.300148,"median":18.274818,"eighty":28.019013,"marketCap":196644272477.68},{"date":"2021-04-01","current":24.108173,"twenty":15.308128,"median":18.305737,"eighty":28.011747,"marketCap":194601172227.48},{"date":"2021-04-09","current":24.426603,"twenty":15.336914,"median":18.352215,"eighty":27.991619,"marketCap":197171541159.64},{"date":"2021-04-16","current":24.594705,"twenty":15.34149,"median":18.380221,"eighty":27.984722,"marketCap":198528460498.63},{"date":"2021-04-23","current":24.625032,"twenty":15.343269,"median":18.411754,"eighty":27.980886,"marketCap":198773259403.94},{"date":"2021-04-30","current":24.094521,"twenty":15.343969,"median":18.498755,"eighty":27.972917,"marketCap":191671912423.89},{"date":"2021-05-07","current":24.8617,"twenty":15.348946,"median":18.532645,"eighty":27.95159,"marketCap":197774820664.93},{"date":"2021-05-14","current":25.153836,"twenty":15.363808,"median":18.565357,"eighty":27.935232,"marketCap":200098770040.64},{"date":"2021-05-21","current":24.924084,"twenty":15.38257,"median":18.594345,"eighty":27.9145,"marketCap":198271089998.22},{"date":"2021-05-28","current":24.965271,"twenty":15.386047,"median":18.628586,"eighty":27.898767,"marketCap":198598732228.7},{"date":"2021-06-04","current":25.428717,"twenty":15.396316,"median":18.694716,"eighty":27.896766,"marketCap":202285445340.91},{"date":"2021-06-11","current":26.151461,"twenty":15.42367,"median":18.776218,"eighty":27.887062,"marketCap":208034875736.78},{"date":"2021-06-18","current":26.227743,"twenty":15.426334,"median":18.837947,"eighty":27.88023,"marketCap":208641694627},{"date":"2021-06-25","current":26.052263,"twenty":15.431826,"median":18.905909,"eighty":27.874868,"marketCap":207245745997.25},{"date":"2021-07-02","current":25.85105,"twenty":15.440199,"median":18.948871,"eighty":27.8383,"marketCap":205645103265.31},{"date":"2021-07-09","current":26.180675,"twenty":15.452123,"median":19.994076,"eighty":27.817206,"marketCap":208267270363.9},{"date":"2021-07-16","current":25.922565,"twenty":15.45839,"median":21.297567,"eighty":27.783193,"marketCap":206214009499.37},{"date":"2021-07-23","current":22.872298,"twenty":15.460519,"median":21.410694,"eighty":27.739049,"marketCap":205484727078.08},{"date":"2021-07-30","current":23.045934,"twenty":15.461717,"median":21.438592,"eighty":27.726383,"marketCap":207044671996.42},{"date":"2021-08-06","current":22.739522,"twenty":15.46988,"median":21.573064,"eighty":27.713849,"marketCap":204291865840.83},{"date":"2021-08-13","current":23.359628,"twenty":15.503564,"median":21.698856,"eighty":27.702531,"marketCap":209862894026.22},{"date":"2021-08-20","current":23.181179,"twenty":15.520325,"median":21.783237,"eighty":27.699801,"marketCap":208259712288.12},{"date":"2021-08-27","current":22.984623,"twenty":15.530062,"median":21.84709,"eighty":27.677778,"marketCap":206493850543.31},{"date":"2021-09-03","current":22.718035,"twenty":15.538322,"median":21.869287,"eighty":27.654974,"marketCap":204098826165.09},{"date":"2021-09-10","current":21.345254,"twenty":15.550583,"median":21.869287,"eighty":27.626214,"marketCap":191765758544.03},{"date":"2021-09-17","current":20.712438,"twenty":15.559277,"median":21.84709,"eighty":27.608358,"marketCap":186080540393.19},{"date":"2021-09-24","current":20.705728,"twenty":15.579952,"median":21.783237,"eighty":27.552824,"marketCap":186020268740.41},{"date":"2021-10-01","current":20.345304,"twenty":15.600577,"median":21.698856,"eighty":27.50635,"marketCap":182782211476.64},{"date":"2021-10-08","current":20.562654,"twenty":15.609566,"median":21.649563,"eighty":27.491371,"marketCap":184734878306.34},{"date":"2021-10-15","current":20.740241,"twenty":15.618942,"median":21.463043,"eighty":27.437499,"marketCap":186330331047.78},{"date":"2021-10-22","current":21.058392,"twenty":15.627389,"median":21.428036,"eighty":27.401594,"marketCap":189188586652.7},{"date":"2021-10-29","current":18.817338,"twenty":15.635032,"median":21.347439,"eighty":27.383461,"marketCap":184541630310.6},{"date":"2021-11-05","current":19.018891,"twenty":15.647289,"median":21.317885,"eighty":27.350089,"marketCap":186518259165.92},{"date":"2021-11-12","current":18.891167,"twenty":15.654532,"median":21.179825,"eighty":27.307652,"marketCap":185265673842.84},{"date":"2021-11-19","current":18.728326,"twenty":15.663321,"median":21.048046,"eighty":27.254761,"marketCap":183668699163.22},{"date":"2021-11-26","current":18.466622,"twenty":15.669452,"median":21.012114,"eighty":27.229251,"marketCap":181102155276.87},{"date":"2021-12-03","current":18.258168,"twenty":15.672299,"median":20.862779,"eighty":27.221869,"marketCap":179057860494.36},{"date":"2021-12-10","current":18.5005,"twenty":15.679373,"median":20.754728,"eighty":27.20819,"marketCap":181434401677.24},{"date":"2021-12-17","current":19.741364,"twenty":15.68813,"median":20.712438,"eighty":27.181553,"marketCap":193603556286.26},{"date":"2021-12-23","current":19.848527,"twenty":15.692775,"median":20.705728,"eighty":27.155854,"marketCap":194654498880},{"date":"2021-12-31","current":20.088424,"twenty":15.701331,"median":20.618532,"eighty":27.138533,"marketCap":197007170988.69},{"date":"2022-01-07","current":20.258584,"twenty":15.705623,"median":20.60602,"eighty":27.121927,"marketCap":198675935418.57},{"date":"2022-01-14","current":20.570686,"twenty":15.723796,"median":20.589637,"eighty":27.105451,"marketCap":201736710825.32},{"date":"2022-01-21","current":19.970714,"twenty":15.736051,"median":20.56667,"eighty":27.061491,"marketCap":195852789238.19},{"date":"2022-01-28","current":19.465055,"twenty":15.746378,"median":20.545058,"eighty":27.059181,"marketCap":190893794335.26},{"date":"2022-02-04","current":8.029227,"twenty":15.720732,"median":20.461012,"eighty":27.056778,"marketCap":192870073011.45},{"date":"2022-02-11","current":8.018981,"twenty":15.689822,"median":20.425342,"eighty":27.053184,"marketCap":192623938080.47},{"date":"2022-02-18","current":8.065272,"twenty":15.689822,"median":20.425342,"eighty":27.053184,"marketCap":193735890248.88},{"date":"2022-02-25","current":8.114918,"twenty":15.689822,"median":20.425342,"eighty":27.053184,"marketCap":194928434328.79},{"date":"2022-03-04","current":7.836403,"twenty":15.689822,"median":20.425342,"eighty":27.053184,"marketCap":188238254501.41},{"date":"2022-03-11","current":7.721781,"twenty":15.689822,"median":20.425342,"eighty":27.053184,"marketCap":185484909723.96},{"date":"2022-03-18","current":8.057829,"twenty":15.689822,"median":20.425342,"eighty":27.053184,"marketCap":193557099512.19},{"date":"2022-03-25","current":8.071441,"twenty":15.689822,"median":20.425342,"eighty":27.053184,"marketCap":193884091322.71},{"date":"2022-04-01","current":8.094547,"twenty":15.689822,"median":20.425342,"eighty":27.053184,"marketCap":194439100004.32},{"date":"2022-04-08","current":8.638654,"twenty":15.689822,"median":20.425342,"eighty":27.053184,"marketCap":207509117437.99},{"date":"2022-04-14","current":8.640519,"twenty":15.689822,"median":20.425342,"eighty":27.053184,"marketCap":207553893767.01},{"date":"2022-04-22","current":8.353937,"twenty":15.689822,"median":20.425342,"eighty":27.053184,"marketCap":200669919872.67},{"date":"2022-04-29","current":8.131471,"twenty":15.665963,"median":20.330649,"eighty":27.053184,"marketCap":196651481774.28},{"date":"2022-05-06","current":7.881676,"twenty":15.621187,"median":20.256294,"eighty":27.03613,"marketCap":190610438695.01},{"date":"2022-05-13","current":7.895122,"twenty":15.554139,"median":20.050708,"eighty":26.799658,"marketCap":190935630327.25},{"date":"2022-05-20","current":7.981506,"twenty":15.46988,"median":19.939865,"eighty":26.712067,"marketCap":193024747095},{"date":"2022-05-27","current":8.181613,"twenty":15.438524,"median":19.636273,"eighty":26.626409,"marketCap":197864120623.02},{"date":"2022-06-03","current":8.00738,"twenty":15.393749,"median":19.478952,"eighty":26.562818,"marketCap":193650479646.81},{"date":"2022-06-10","current":7.624373,"twenty":15.34334,"median":19.163283,"eighty":26.481397,"marketCap":184387844631.82},{"date":"2022-06-17","current":7.304054,"twenty":15.298712,"median":19.077284,"eighty":26.418719,"marketCap":176641242394.35},{"date":"2022-06-24","current":7.582309,"twenty":15.27964,"median":18.986834,"eighty":26.364561,"marketCap":183370574720.06},{"date":"2022-07-01","current":7.493877,"twenty":15.250273,"median":18.900841,"eighty":26.314464,"marketCap":181231913048.72},{"date":"2022-07-08","current":7.606086,"twenty":15.23199,"median":18.869162,"eighty":26.291679,"marketCap":183945576164.31},{"date":"2022-07-15","current":7.58856,"twenty":15.202136,"median":18.806098,"eighty":26.232109,"marketCap":183521723409.93},{"date":"2022-07-22","current":8.19561,"twenty":15.18337,"median":18.71718,"eighty":26.166494,"marketCap":188351517085.2},{"date":"2022-07-29","current":8.158045,"twenty":15.157076,"median":18.647438,"eighty":26.132159,"marketCap":187488206041.27},{"date":"2022-08-05","current":8.078369,"twenty":15.110436,"median":18.578085,"eighty":26.065871,"marketCap":185657067852.22},{"date":"2022-08-12","current":8.066066,"twenty":15.073457,"median":18.515669,"eighty":25.940642,"marketCap":185374335649.61},{"date":"2022-08-19","current":8.123102,"twenty":15.02629,"median":18.4837,"eighty":25.886111,"marketCap":186685117272.05},{"date":"2022-08-26","current":7.921009,"twenty":14.971809,"median":18.427077,"eighty":25.833627,"marketCap":182040613492.93},{"date":"2022-09-02","current":7.69931,"twenty":14.889831,"median":18.390521,"eighty":25.781076,"marketCap":176945538997.44},{"date":"2022-09-09","current":7.839444,"twenty":14.847478,"median":18.352215,"eighty":25.737059,"marketCap":180166100535.63},{"date":"2022-09-16","current":7.639838,"twenty":14.800639,"median":18.279395,"eighty":25.69413,"marketCap":175578771828.6},{"date":"2022-09-23","current":7.200687,"twenty":14.715721,"median":18.250058,"eighty":25.606633,"marketCap":165486184420.18},{"date":"2022-09-30","current":7.309364,"twenty":14.666961,"median":18.233974,"eighty":25.536644,"marketCap":167983801405.08},{"date":"2022-10-07","current":7.233971,"twenty":14.612953,"median":18.210204,"eighty":25.43593,"marketCap":166251109031.05},{"date":"2022-10-14","current":7.191933,"twenty":14.497159,"median":18.168977,"eighty":25.32345,"marketCap":165284995916.46},{"date":"2022-10-21","current":7.25195,"twenty":14.457826,"median":18.113862,"eighty":25.286138,"marketCap":166664300685.15},{"date":"2022-10-28","current":7.929368,"twenty":14.315805,"median":18.077533,"eighty":25.233079,"marketCap":172836429210.02},{"date":"2022-11-04","current":8.027551,"twenty":14.283277,"median":18.007982,"eighty":25.152421,"marketCap":174976531233.09},{"date":"2022-11-11","current":8.242312,"twenty":14.244857,"median":17.98094,"eighty":25.087357,"marketCap":179657664851.58},{"date":"2022-11-18","current":8.457603,"twenty":14.191615,"median":17.955359,"eighty":24.985599,"marketCap":184350366168.97},{"date":"2022-11-25","current":8.657467,"twenty":14.143838,"median":17.845766,"eighty":24.944555,"marketCap":188706817286.19},{"date":"2022-12-02","current":8.838391,"twenty":14.078613,"median":17.783631,"eighty":24.901055,"marketCap":192650402692.03},{"date":"2022-12-09","current":9.046654,"twenty":14.034813,"median":17.713631,"eighty":24.828177,"marketCap":197189931786.84},{"date":"2022-12-16","current":8.906442,"twenty":14.013992,"median":17.636168,"eighty":24.769512,"marketCap":194133722263.41},{"date":"2022-12-23","current":8.960744,"twenty":13.971607,"median":17.554825,"eighty":24.727245,"marketCap":195317323645.23},{"date":"2022-12-30","current":8.920871,"twenty":13.914951,"median":17.505765,"eighty":24.703969,"marketCap":194448241062.22},{"date":"2023-01-06","current":9.093242,"twenty":13.856188,"median":17.48301,"eighty":24.625204,"marketCap":198205406557.8},{"date":"2023-01-13","current":9.002411,"twenty":13.821776,"median":17.460761,"eighty":24.583673,"marketCap":196225557627.91},{"date":"2023-01-20","current":9.051584,"twenty":13.776842,"median":17.424808,"eighty":24.543498,"marketCap":197297374275.26},{"date":"2023-01-27","current":8.847624,"twenty":13.673815,"median":17.405208,"eighty":24.464769,"marketCap":192851676130.76},{"date":"2023-02-03","current":26.243556,"twenty":13.627087,"median":17.400788,"eighty":24.459661,"marketCap":182523930790.97},{"date":"2023-02-10","current":26.294961,"twenty":13.627087,"median":17.400788,"eighty":24.459661,"marketCap":182881448586.32},{"date":"2023-02-17","current":26.374513,"twenty":13.627087,"median":17.400788,"eighty":24.459661,"marketCap":183434736554.71},{"date":"2023-02-24","current":26.177477,"twenty":13.627087,"median":17.400788,"eighty":24.459661,"marketCap":182064354704.07},{"date":"2023-03-03","current":25.765519,"twenty":13.627087,"median":17.400788,"eighty":24.459661,"marketCap":179199184580.8},{"date":"2023-03-10","current":24.700467,"twenty":13.627087,"median":17.400788,"eighty":24.459661,"marketCap":171791749395.01},{"date":"2023-03-17","current":26.915798,"twenty":13.627087,"median":17.400788,"eighty":24.459661,"marketCap":187199370174.87},{"date":"2023-03-24","current":27.246033,"twenty":13.627087,"median":17.400788,"eighty":24.543498,"marketCap":189496154839.06},{"date":"2023-03-31","current":30.054098,"twenty":13.630004,"median":17.402998,"eighty":24.587255,"marketCap":209026250254.21},{"date":"2023-04-06","current":31.533443,"twenty":13.630004,"median":17.402998,"eighty":24.625118,"marketCap":219315097125.45},{"date":"2023-04-14","current":32.274976,"twenty":13.627087,"median":17.400788,"eighty":24.706379,"marketCap":224472453860.2},{"date":"2023-04-21","current":32.553317,"twenty":13.627087,"median":17.400788,"eighty":24.770643,"marketCap":226408322073.89},{"date":"2023-04-28","current":30.395591,"twenty":13.627087,"median":17.400788,"eighty":24.870311,"marketCap":213559421622.35},{"date":"2023-05-05","current":31.378954,"twenty":13.624171,"median":17.400508,"eighty":24.92381,"marketCap":220468531572.95},{"date":"2023-05-12","current":30.870482,"twenty":13.624171,"median":17.400508,"eighty":24.976352,"marketCap":216896002905.77},{"date":"2023-05-19","current":29.854888,"twenty":13.624171,"median":17.400508,"eighty":25.035144,"marketCap":209760441249.27},{"date":"2023-05-26","current":29.284412,"twenty":13.624171,"median":17.400508,"eighty":25.151225,"marketCap":205752279633.25},{"date":"2023-06-02","current":29.357697,"twenty":13.624171,"median":17.400508,"eighty":25.224214,"marketCap":206267176913.22},{"date":"2023-06-09","current":29.886389,"twenty":13.624171,"median":17.400508,"eighty":25.298929,"marketCap":209981771535.32},{"date":"2023-06-16","current":30.321305,"twenty":13.624171,"median":17.400508,"eighty":25.414052,"marketCap":213037486310.78},{"date":"2023-06-23","current":30.190139,"twenty":13.621254,"median":17.400228,"eighty":25.482171,"marketCap":212115917863.59},{"date":"2023-06-30","current":29.926736,"twenty":13.621254,"median":17.400228,"eighty":25.530882,"marketCap":210265246516.29},{"date":"2023-07-07","current":28.234527,"twenty":13.621254,"median":17.400228,"eighty":25.631737,"marketCap":198375788384.16},{"date":"2023-07-14","current":29.505671,"twenty":13.621254,"median":17.400228,"eighty":25.721137,"marketCap":207306851165.12},{"date":"2023-07-21","current":28.497251,"twenty":13.702614,"median":17.40584,"eighty":25.765158,"marketCap":217946975867.36},{"date":"2023-07-28","current":28.10544,"twenty":13.702614,"median":17.431322,"eighty":25.810163,"marketCap":214950408672.37},{"date":"2023-08-04","current":27.560871,"twenty":13.702614,"median":17.466898,"eighty":25.855767,"marketCap":210785535427.99},{"date":"2023-08-11","current":28.108004,"twenty":13.702614,"median":17.491087,"eighty":25.920889,"marketCap":214970019886.42},{"date":"2023-08-18","current":27.500668,"twenty":13.716822,"median":17.543114,"eighty":25.999939,"marketCap":210325106917.85},{"date":"2023-08-25","current":27.490856,"twenty":13.716822,"median":17.630823,"eighty":26.112124,"marketCap":210250065949.08},{"date":"2023-09-01","current":27.33691,"twenty":13.716822,"median":17.676024,"eighty":26.137251,"marketCap":209072687172.76},{"date":"2023-09-08","current":26.684355,"twenty":13.831992,"median":17.775785,"eighty":26.164037,"marketCap":204081948408.26},{"date":"2023-09-15","current":27.8918,"twenty":13.863753,"median":17.829937,"eighty":26.195299,"marketCap":213316484771.89},{"date":"2023-09-22","current":27.529162,"twenty":13.863753,"median":17.948734,"eighty":26.256036,"marketCap":210543032637.27},{"date":"2023-09-29","current":27.704599,"twenty":13.863753,"median":17.977965,"eighty":26.294822,"marketCap":211884773857.62},{"date":"2023-10-06","current":26.136777,"twenty":13.863753,"median":17.998187,"eighty":26.307358,"marketCap":199894070259.72},{"date":"2023-10-13","current":26.099935,"twenty":13.931808,"median":18.076116,"eighty":26.318536,"marketCap":199612304286.36},{"date":"2023-10-20","current":25.606741,"twenty":13.931808,"median":18.102011,"eighty":26.318536,"marketCap":195840357582.32},{"date":"2023-10-27","current":24.415836,"twenty":13.914417,"median":18.144394,"eighty":26.326723,"marketCap":191322491088.71},{"date":"2023-11-03","current":24.121849,"twenty":13.914417,"median":18.186711,"eighty":26.326723,"marketCap":189018809684.75},{"date":"2023-11-10","current":24.455041,"twenty":13.914417,"median":18.226261,"eighty":26.326723,"marketCap":191629701060.59},{"date":"2023-11-17","current":24.852995,"twenty":13.914417,"median":18.240532,"eighty":26.326723,"marketCap":194748066897.24},{"date":"2023-11-24","current":25.763747,"twenty":13.914417,"median":18.264257,"eighty":26.326723,"marketCap":201884721514.42},{"date":"2023-12-01","current":25.681448,"twenty":13.914417,"median":18.308684,"eighty":26.326723,"marketCap":201239827121.68},{"date":"2023-12-08","current":25.351528,"twenty":13.918256,"median":18.360699,"eighty":26.322856,"marketCap":198654572969.12},{"date":"2023-12-15","current":25.72582,"twenty":13.918256,"median":18.394754,"eighty":26.322856,"marketCap":201587524553.81},{"date":"2023-12-22","current":25.978676,"twenty":13.918256,"median":18.447118,"eighty":26.322856,"marketCap":203568905697.84},{"date":"2023-12-29","current":26.529514,"twenty":13.914417,"median":18.483927,"eighty":26.348002,"marketCap":207885278188.64},{"date":"2024-01-05","current":27.901829,"twenty":13.910577,"median":18.51381,"eighty":26.370883,"marketCap":218638738608.88},{"date":"2024-01-12","current":28.036514,"twenty":13.910577,"median":18.571472,"eighty":26.422243,"marketCap":219694129152.93},{"date":"2024-01-19","current":28.352927,"twenty":13.906738,"median":18.628586,"eighty":26.470944,"marketCap":222173534575.94},{"date":"2024-01-26","current":27.949174,"twenty":13.910577,"median":18.684776,"eighty":26.521392,"marketCap":219009721879.32},{"date":"2024-02-02","current":14.397684,"twenty":13.910577,"median":18.71718,"eighty":26.537684,"marketCap":213805607321.99},{"date":"2024-02-09","current":13.900537,"twenty":13.868427,"median":18.71718,"eighty":26.537684,"marketCap":206422982529.79},{"date":"2024-02-16","current":13.813113,"twenty":13.687988,"median":18.71718,"eighty":26.537684,"marketCap":205124721398.18},{"date":"2024-02-23","current":14.305017,"twenty":13.687988,"median":18.71718,"eighty":26.537684,"marketCap":212429491580.85},{"date":"2024-03-01","current":14.052638,"twenty":13.704706,"median":18.708576,"eighty":26.536229,"marketCap":208681673875.32},{"date":"2024-03-08","current":13.812509,"twenty":13.704706,"median":18.708576,"eighty":26.536229,"marketCap":205115751567.13},{"date":"2024-03-15","current":13.350493,"twenty":13.599085,"median":18.708576,"eighty":26.536229,"marketCap":198254813990.44},{"date":"2024-03-22","current":14.193287,"twenty":13.599085,"median":18.708576,"eighty":26.536229,"marketCap":210770303493.35},{"date":"2024-03-28","current":14.305417,"twenty":13.599085,"median":18.708576,"eighty":26.536229,"marketCap":212435439752.63},{"date":"2024-04-05","current":14.023817,"twenty":13.576499,"median":18.71718,"eighty":26.537684,"marketCap":208253683585.27},{"date":"2024-04-12","current":13.933033,"twenty":13.576499,"median":18.71718,"eighty":26.537684,"marketCap":206905536915.4},{"date":"2024-04-19","current":13.841097,"twenty":13.576499,"median":18.71718,"eighty":26.537684,"marketCap":205540289930.65},{"date":"2024-04-26","current":13.116641,"twenty":13.098986,"median":18.708576,"eighty":26.536229,"marketCap":199963177263.62},{"date":"2024-05-03","current":12.901312,"twenty":12.986611,"median":18.708576,"eighty":26.536229,"marketCap":196680491183.63},{"date":"2024-05-10","current":13.62556,"twenty":12.986611,"median":18.708576,"eighty":26.536229,"marketCap":207721668262.32},{"date":"2024-05-17","current":13.811142,"twenty":12.986611,"median":18.708576,"eighty":26.536229,"marketCap":210550870720.47},{"date":"2024-05-24","current":13.427426,"twenty":12.986611,"median":18.708576,"eighty":26.536229,"marketCap":204701108813.04},{"date":"2024-05-31","current":13.797418,"twenty":12.986611,"median":18.708576,"eighty":26.536229,"marketCap":210341631436.51},{"date":"2024-06-07","current":14.246068,"twenty":12.986611,"median":18.708576,"eighty":26.536229,"marketCap":217181308721.48},{"date":"2024-06-14","current":14.220001,"twenty":12.986611,"median":18.708576,"eighty":26.536229,"marketCap":216783909228.96},{"date":"2024-06-21","current":14.123248,"twenty":12.9792,"median":18.71718,"eighty":26.537684,"marketCap":215308906730.59},{"date":"2024-06-28","current":14.334626,"twenty":12.939152,"median":18.738531,"eighty":26.54537,"marketCap":218531380215.61},{"date":"2024-07-05","current":14.368048,"twenty":12.939152,"median":18.738531,"eighty":26.54537,"marketCap":219040892779.52},{"date":"2024-07-12","current":14.979512,"twenty":12.939152,"median":18.738531,"eighty":26.54537,"marketCap":228362653471.36},{"date":"2024-07-15","current":14.823193,"twenty":12.939152,"median":18.738531,"eighty":26.54537,"marketCap":225979585099.3},{"date":"2024-08-02","current":13.829686,"twenty":9.174052,"median":18.796476,"eighty":26.561516,"marketCap":223695182982.23},{"date":"2024-08-09","current":13.947897,"twenty":9.174052,"median":18.796476,"eighty":26.561516,"marketCap":225607243407.28},{"date":"2024-08-16","current":14.29468,"twenty":9.174052,"median":18.796476,"eighty":26.561516,"marketCap":231216434977.84},{"date":"2024-08-23","current":14.748882,"twenty":9.174052,"median":18.796476,"eighty":26.561516,"marketCap":238563170201.28},{"date":"2024-08-30","current":15.071422,"twenty":9.174052,"median":18.796476,"eighty":26.561516,"marketCap":243780244488.86},{"date":"2024-09-06","current":14.566348,"twenty":9.174052,"median":18.796476,"eighty":26.561516,"marketCap":235610682264},{"date":"2024-09-13","current":14.392965,"twenty":9.174052,"median":18.796476,"eighty":26.561516,"marketCap":232806208493.04},{"date":"2024-09-20","current":14.62573,"twenty":9.174052,"median":18.796476,"eighty":26.561516,"marketCap":236571180766.96},{"date":"2024-09-27","current":14.474714,"twenty":9.174052,"median":18.796476,"eighty":26.561516,"marketCap":234128501124.19},{"date":"2024-10-04","current":14.328493,"twenty":9.174052,"median":18.796476,"eighty":26.561516,"marketCap":231763377879.44},{"date":"2024-10-11","current":14.53281,"twenty":9.174052,"median":18.796476,"eighty":26.561516,"marketCap":235068192144.32},{"date":"2024-10-18","current":14.616396,"twenty":9.174052,"median":18.796476,"eighty":26.561516,"marketCap":236420201553.07},{"date":"2024-10-25","current":14.249607,"twenty":9.174052,"median":18.796476,"eighty":26.561516,"marketCap":230487389403.66},{"date":"2024-10-31","current":12.316052,"twenty":9.174052,"median":18.796476,"eighty":26.561516,"marketCap":216799455601.16},{"date":"2024-11-08","current":12.084082,"twenty":9.173718,"median":18.806098,"eighty":26.562609,"marketCap":212716082431.8},{"date":"2024-11-15","current":11.7431,"twenty":9.173718,"median":18.806098,"eighty":26.562609,"marketCap":206713778876.88},{"date":"2024-11-22","current":12.008212,"twenty":9.173718,"median":18.806098,"eighty":26.562609,"marketCap":211380543419.03},{"date":"2024-11-29","current":11.989078,"twenty":9.173718,"median":18.806098,"eighty":26.562609,"marketCap":211043738444.04},{"date":"2024-12-06","current":11.601044,"twenty":9.173718,"median":18.806098,"eighty":26.562609,"marketCap":204213183580.32},{"date":"2024-12-13","current":11.217052,"twenty":9.173718,"median":18.806098,"eighty":26.562609,"marketCap":197453767709},{"date":"2024-12-20","current":10.977297,"twenty":9.173718,"median":18.806098,"eighty":26.562609,"marketCap":193233357029.33},{"date":"2024-12-27","current":11.209016,"twenty":9.173718,"median":18.806098,"eighty":26.562609,"marketCap":197312315222.73},{"date":"2025-01-03","current":11.085825,"twenty":9.173718,"median":18.806098,"eighty":26.562609,"marketCap":195143766953.58},{"date":"2025-01-10","current":11.339502,"twenty":9.173384,"median":18.806415,"eighty":26.563702,"marketCap":199609258842.55},{"date":"2025-01-17","current":11.132461,"twenty":9.173384,"median":18.806415,"eighty":26.563702,"marketCap":195964707489.63},{"date":"2025-01-24","current":11.289573,"twenty":9.173384,"median":18.806415,"eighty":26.563702,"marketCap":198730349797.09},{"date":"2025-01-31","current":11.960588,"twenty":9.173384,"median":18.806415,"eighty":26.563702,"marketCap":210542226015.58},{"date":"2025-02-07","current":17.70064,"twenty":9.173384,"median":18.806415,"eighty":26.563702,"marketCap":211363341050.81},{"date":"2025-02-14","current":17.440689,"twenty":9.173384,"median":18.752272,"eighty":26.563702,"marketCap":208259269606.51},{"date":"2025-02-21","current":18.037424,"twenty":9.173384,"median":18.672846,"eighty":26.563702,"marketCap":215384882550.78},{"date":"2025-02-28","current":17.963541,"twenty":9.173384,"median":18.676064,"eighty":26.563702,"marketCap":214502647775.32},{"date":"2025-03-07","current":18.870832,"twenty":9.17305,"median":18.699973,"eighty":26.564795,"marketCap":225336612035.23},{"date":"2025-03-14","current":18.012021,"twenty":9.17305,"median":18.728326,"eighty":26.564795,"marketCap":215081544614.48},{"date":"2025-03-21","current":18.611632,"twenty":9.17305,"median":18.728326,"eighty":26.564795,"marketCap":222241493733.77},{"date":"2025-03-28","current":17.773649,"twenty":9.17305,"median":18.728326,"eighty":26.564795,"marketCap":212235145303.4},{"date":"2025-04-04","current":17.039027,"twenty":9.17305,"median":18.728326,"eighty":26.564795,"marketCap":203463019508.1},{"date":"2025-04-11","current":16.509973,"twenty":9.173384,"median":18.721558,"eighty":26.563702,"marketCap":197145582403.7},{"date":"2025-04-17","current":17.580919,"twenty":9.173384,"median":18.721558,"eighty":26.563702,"marketCap":209933754161.38},{"date":"2025-04-25","current":17.764291,"twenty":9.17305,"median":18.728326,"eighty":26.564795,"marketCap":212123395369.82},{"date":"2025-05-02","current":17.243172,"twenty":9.17305,"median":18.728326,"eighty":26.564795,"marketCap":221729945789.59}],"updateTime":1746505363002}}}